https://scholars.lib.ntu.edu.tw/handle/123456789/525246
標題: | Efficacy of a Novel Palivizumab Prophylaxis Protocol for Respiratory Syncytial Virus Infection in Congenital Heart Disease: A Multicenter Study | 作者: | SHUENN-NAN CHIU Wang J.-N. Fu Y.-C. Chung H.-T. LING-YIN CHANG MEI-HWAN WU Hua Y.-C. MING-TAI LIN CHUN-WEI LU CHUN-AN CHEN Wu J.-M. JOU-KOU WANG |
公開日期: | 2018 | 出版社: | Mosby Inc. | 卷: | 195 | 起(迄)頁: | 108-1140 | 來源出版物: | Journal of Pediatrics | 摘要: | Objective: To analyze the efficacy of a novel palivizumab protocol for hemodynamically significant congenital heart disease (hsCHD) in subtropical areas without clear respiratory syncytial virus seasonality. Study design: Since July 2013, the National Health Insurance program has provided reimbursement for palivizumab prophylaxis with a novel monthly protocol in selected patients with hsCHD under 1 year of age. We performed a multicenter study to assess the trend of respiratory syncytial virus hospitalizations in patients with hsCHD from 2010 to 2016 during the prepalivizumab, transition, and postpalivizumab periods, and compared treatment and propensity-matched control groups. Results: A total of 747 patients were enrolled in the study group and 809 in the control group. The male:female was 836:720. Cyanotic CHD was observed in 42.9% of patients. The mean age at diagnosis of CHD was 32.9 days. After 516 685 patient-days of follow-up and a mean of 3.9 doses of palivizumab in the treatment group, respiratory syncytial virus hospitalization rates decreased by 53% and 49% before and after match compared with the control group (P =.009 and.029, respectively). Hospitalization days and intensive care unit admission rate also decreased similarly in the treatment group. The efficacy of this protocol was more prominent in patients with cyanotic hsCHD. The annual respiratory syncytial virus-associated hospitalization rates also decreased significantly from the prepalivizumab to the palivizumab period (from 4.8% to 2.0%; P =.038). Conclusion: Palivizumab prophylaxis through the novel monthly protocol for patients with hsCHD is effective in reducing respiratory syncytial virus-related hospitalizations. ? 2017 Elsevier Inc. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85041129426&doi=10.1016%2fj.jpeds.2017.11.044&partnerID=40&md5=c49ebf7c13ea00b39274aeef2ab58265 https://scholars.lib.ntu.edu.tw/handle/123456789/525246 |
ISSN: | 0022-3476 | DOI: | 10.1016/j.jpeds.2017.11.044 | SDG/關鍵字: | palivizumab; antivirus agent; palivizumab; age; antiviral therapy; Article; child; cohort analysis; congenital heart disease; controlled study; cyanotic heart disease; drug efficacy; female; follow up; hospital admission; hospitalization; human; infant; infection prevention; intensive care unit; major clinical study; male; multicenter study; patient compliance; preschool child; priority journal; respiratory syncytial virus infection; seasonal variation; case control study; clinical trial; complication; congenital heart malformation; respiratory syncytial virus infection; statistics and numerical data; Taiwan; tropic climate; Antiviral Agents; Case-Control Studies; Female; Heart Defects, Congenital; Hospitalization; Humans; Infant; Male; Palivizumab; Respiratory Syncytial Virus Infections; Taiwan; Tropical Climate |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。